Safety-Related Labeling Changes
Updated recommendations to minimise the risks of malignancy, major adverse cardiovascular events, serious infections, Venous thromboembolism and mortality with use of Janus kinase inhibitors
Trade Name
Rinvoq
Updated Section
4.4 Special Warnings and Special Precautions for Use
Month
Apr,2023